Thursday, November 16th 2023
Genetic Engineered Lymphocytes 101 (Educational Program)

Topics

• Introduction to Cellular Immunotherapy (Basic component of CAR T cells)
  Thanyavi Chinsuwan, MD, Chulalongkorn University

• Genetic Engineering Technologies I (Basic techniques)
  Jatuporn Sujjitjoon, PhD, Mahidol University

• Genetic Engineering Technologies II (Delivery Systems)
  Wannakorn Khopanlert, MD, Prince of Songkla University

• Genetic Engineering Technologies III (Gene Editing)
  Chatchanan Doungkamchan, MD, PhD, Chulalongkorn University

• Non-viral CRISPR CAR-T cells going viral
  Hyatt Balke Want, MD, Stanford University

• Memory-rich CAR-T cell engineering by piggyBac transposon system for solid malignancies
  Shigeki Yagyu, MD, PhD, Shinshu University

• mRNA as gene editing application for cell therapy
  Supannikar Tawinwung, PhD, Chulalongkorn University

Friday, November 17th 2023
Genetic Engineered Lymphocytes 101 (Educational Program)

Topics

• Opening Ceremony
  Introduction to hub of talent program 
  NRCT, Nattiya Hirankarn, MD, PhD, Professor
  Director, Cancer Immunotherapy Excellence Center, Chulalongkorn University

• Advancements in Chimeric Antigen Receptor T Cell Therapy and Beyond”
  Pa-thai Yenchitsomanus, PhD, Professor
  Director, Siriraj Center of Research Excellence for Cancer Immunotherapy, Mahidol University

• Development and clinical application of piggyBac-based CAR-T cells for hematological malignancies
  Shoji Saito, MD, PhD, Assistant Professor
  Department of Pediatrics Shinshu University School of Medicine

• International collaboration of CAR-T cell therapy using non-viral vector system
  Yoshiyuki Takahashi MD, Ph.D, Professor and Chairman, Department of Pediatrics
  Nagoya University Graduate School of Medicine

• Development of Eva1, a tumor-specific antigen, targeting chimeric antigen receptor T cells and insights from the development process
  Seitaro Terakura, MD, PhD, Professor
  Nagoya University Graduate School of Medicine

• A constitutively active IL-7 receptor augments the activity of CLL-1 CAR T-cells against AML
  Haruko Tashiro, MD, PhD, Professor
  Department of Hematology/Oncology, Teikyo University School of Medicine

• CAR T-cell immunotherapy of solid tumours: moving through the generations.
  John Maher, MD, PhD, Professor
  Division of Cancer Studies King’s College London

• Future Perspective in Genetic Engineered Immune Cells
  Alex Mclellan, PhD, Professor
  Dept. Microbiology & Immunology, Otago University

Friday, November 17th 2023
Genetic Engineered Lymphocytes 101 (Educational Program)

(Recorded VDO) Short Oral Presentation session I  
Chair: Thanyavi Chinsuwan, MD
Suyanee Thongchot, PhD

O1: Generation of autologous patient hematopoietic stem cell-derived T-lymphocyte for adoptive T-cell therapy
Kajornkiat Maneechai
O2: Assessing the Influence of Non-signaling Domains on TIM3 CAR T Cell Development for the Treatment of AML
Kristine Cate Pe
O3: Development of a novel anti-human B7 homolog 3 antibody for designing CAR-T cell against solid tumors
Thananya Inthanachai
O4: Development of a chimeric antigen receptor targeting folate receptor alpha from human variable domain of heavy chain (VH) antibody fragment
Nithidol Sakunrangsit

(Recorded VDO) Short Oral presentation session II
Chair: Jakkrawadee Julamanee, MD, PhD
Piriya Luangwattananun, PhD

O5: Personalized neoantigen immunotherapy platform for breast cancer
Suyanee Thongchot
O6: Tumor-Targeted Photothermal Immunogenic Nanovaccine Induced Efficient Cancer Immunotherapy
Raju Vivek
O7: Potent Application of Humanized Anti-cMET Single Chain Variable Fragment in the Era of Chimeric Antigen Receptor (CAR)-Engineered NK Cells for Cholangiocarcinoma Immunotherapy
Chutipa Chiawpanit
O8: Development of adoptive transfer therapy harnessing  T cells and NK cells against cholangiocarcinoma
Inthu-on Kulma

November 16-17, 2023

P1: Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti PD-1 IgG antibody.
(Nattarika Khuisangeam)
P2: Spatial transcriptomics of cancer-associated fibroblasts indicate potential effect on immune microenvironment in high tumor budding breast cancer. (Pimchanok Phankeaw)
P3: The Effect of Cannabidivarin on T-cell Line Proliferation and Activation. (Wilai Laolee)
P4: Development of mRNA-based off-the-shelf CAR T cells. (Thanyaporn Buakaew)
P5: Enhancement of T cell-mediated antitumor efficacy using a bispecific T cell engager targeting integrin αvβ6 against cholangiocarcinoma. (Kwanpirom Suwanchiwasiri)
P6: Targeting Lung Adenocarcinoma using anti-Folate receptor alpha CAR-T cell combining with immune checkpoint blockade molecule. (Yupanun Wutti-in)
P7: Immune landscape discovery of triple-negative breast cancer. (Suparada Khanaruksombat)
P8: The Efficacy and Safety of Chimeric Antigen Receptor-Modified T (CAR-T) Cell Therapy in Lymphoma: Systematic Review and Meta-Analysis. (I Gede Krisna Arim Sadeva)
P9: Potential Immunotherapy of Various Plant-Derived Monoclonal Antibodies in Colorectal Cancer: A Literature Review.
(Renita Gusti Wardhani)
P10: Anti-PD-1 Monoclonal Antibody as Immune Checkpoint Inhibitor for Newly Diagnosed & Recurrent Glioblastoma: A Systematic Review and Meta-Analysis of Randomized. (Valensa Yosephi)
P11: The Efficacy and Safety of Chimeric Antigen Receptor-Modified T (CAR-T) Cell Therapy in Multiple Myeloma: A Systematic Review and Meta-Analysis. (Christo Timothy)
P12: Evaluation on Efficacy and Safety of Chimeric Antigen Receptor-Modified T (CAR-T) Cell Therapy in Leukemia: A 5-Year Updated Systematic Review and Meta-Analysis. (I Gede Wikania Wira Wiguna)
P13: Nanobodies in Breast Cancer Immunotherapy: Targeting Subtypes for Personalized Treatment. (Jefferson caesario)
P14: Clinical Scale CAR-T Manufacturing Process with Reduced IL-6 Cytokine for Immunotherapy. (Fazil Turbe)
P15: Cordycepin enhanced anti-cancer activity of peripheral blood mononuclear cells against. (Boonyanuch Ramwarungkura)